

CITATION REPORT

List of articles citing

Sildenafil in primary pulmonary hypertension

DOI: 10.1056/nejm200011023431814

New England Journal of Medicine, 2000, 343, 1342.

Source: <https://exaly.com/paper-pdf/31839874/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
250	Current management of primary pulmonary hypertension. 2001 , 15, 801-17		8
249	Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. 2001 , 10, 1291-308		16
248	Sildenafil for pulmonary hypertension. 2001 ,		1
247	Physiologic basis for the treatment of pulmonary hypertension. 2001 , 138, 287-97		62
246	Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. 2001 , 104, 1218-22		345
245	Progress in, and future prospects for, the treatment of primary pulmonary hypertension. 2001 , 86, 603-4		4
244	New treatments for pulmonary arterial hypertension. 2002 , 165, 1209-16		101
243	Treatment of primary pulmonary hypertension -- the next generation. <i>New England Journal of Medicine</i> , 2002 , 346, 933-5	59.2	25
242	Recent advances in pulmonary vascular disease. 2002 , 14, 292-7		25
241	Primary pulmonary hypertension and cor pulmonale. 2002 , 10, 265-78		5
240	Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. 2002 , 100, 1516-7		53
239	Treatment of Primary Pulmonary Hypertension. 2002 , 32, 185-187		
238	Chapter 5: Recent advances in pulmonary hypertension therapy. 2002 , 37, 41-52		1
237	AML, angiogenesis, and prognostic variables. 2002 , 100, 1517-8		3
236	Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension. 2002 , 112, 428-30		16
235	Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. 2002 , 105, 2398-403		508
234	Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. 2002 , 86, 131-41		64

233	[Pulmonary hypertension: current criteria for diagnosis and treatment]. 2002 , 118, 590-6	0
232	Sildenafil--a possible treatment for acute pulmonary hypertension during cardiac surgery. 2002 , 15, 13-5	2
231	Emerging medical therapies for pulmonary arterial hypertension. 2002 , 45, 213-24	35
230	Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. 2002 , 90, 677-80	135
229	[Cardio-vascular effects of sildenafil: new data]. 2002 , 51, 341-5	3
228	quoi de neuf en cardiologie p̄diatrique en 2002. 2002 , 15, 275-279	1
227	Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?. 2002 , 46, 1997-2009	36
226	Medikament̄e Behandlung von Patienten mit chronischer Pulmonaler Hypertonie. 2002 , 16, 131-141	
225	Clinical update on sildenafil citrate. 2002 , 53, 219-23	10
224	Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. 2002 , 32, 424-6	11
223	New therapeutics that antagonize endothelin: promises and frustrations. 2002 , 1, 986-1001	113
222	Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. 2002 , 137, 1187-94	103
221	The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. 2003 , 8, 5-21	51
220	DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats. 2003 , 26, 612-9	12
219	Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. 2003 , 29, 1996-2003	157
218	Sildenafil and assessment of pulmonary arterial reactivity in heart failure. 2003 , 9, 176-8	3
217	Effects of sildenafil on cardiopulmonary responses during stress. 2003 , 169, 1417-21	6
216	Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. 2003 , 78, 1207-13	91

215	[Sildenafil as a substitute for subcutaneous prostacyclin in pulmonary hypertension]. 2003 , 39, 476-7	1
214	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. 2003 , 108, 239-44	124
213	Phosphodiesterases as therapeutic targets. 2003 , 61, 685-91	43
212	Primary pulmonary hypertension. 2003 , 361, 1533-44	428
211	Sildenafil in secondary pulmonary hypertension. 2003 , 89, 101-2	7
210	[Use of oral sildenafil (Viagra) in pulmonary hypertension after cardiac pediatric surgery]. 2003 , 22, 140-3	5
209	Cyclic GMP phosphodiesterases and regulation of smooth muscle function. 2003 , 93, 280-91	420
208	Prostanoids for pulmonary arterial hypertension. 2003 , 2, 123-37	100
207	DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. 2003 , 31, 517-28	15
206	Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy. 2003 , 12, 321-3	16
205	Pathophysiology of pulmonary hypertension due to lung disease. 2003 , 9, 131-8	43
204	Critical care in cardiovascular medicine. 2003 , 15, 443-53	32
203	Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. 2003 , 123, 1293-5	101
202	Treatment of pulmonary arterial hypertension: a step forward. 2003 , 124, 8-11	5
201	Sildenafil for pulmonary arterial hypertension: exciting, but protection required. 2003 , 123, 989-92	24
200	References. 601-868	
199	HIV-associated pulmonary hypertension: diagnosis and treatment. 2003 , 40, 197-207	3
198	Sildenafil: Pulmonary Hypertension (Pediatric, Neonatal). 2003 , 38, 646-651	

197	Treatment of Pulmonary Arterial Hypertension with Sildenafil. 2004 , 39, 243-253		2
196	Sildenafil for pulmonary arterial hypertension: still waiting for evidence. 2004 , 169, 6-7		17
195	Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. 2004 , 169, 39-45		207
194	Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. 2004 , 125, 644-51		29
193	Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. 2004 , 55, 413-8		67
192	The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension. 2004 , 213-229		
191	Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. <i>European Journal of Heart Failure</i> , 2004 , 6, 615-7	12.3	35
190	Infant pertussis deaths and the management of cardiovascular compromise. 2004 , 40, 230-2		19
189	Endothelin and pulmonary arterial hypertension. 2004 , 34, 442-53		29
188	Phosphodiesterase inhibitors in the management of primary pulmonary hypertension. 2004 , 19, 74-9		1
187	Role of the cardiologist: Clinical aspects of managing erectile dysfunction. 2004 , 27, 3-7		7
186	Therapie der pulmonalen Hypertonie. 2004 , 1, 95-101		2
185	Pulmonary arterial hypertension in children. 2004 , 38, 2-22		123
184	Molecular biology of primary pulmonary hypertension. 2004 , 22, 417-29, vi		11
183	[Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension: report of 4 cases]. 2004 , 122, 64-6		4
182	Hypertension artérielle pulmonaire. 2004 , 1, 46-68		0
181	Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. 2004 , 43, 1149-53		395
180	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. 2004 , 43, 81S-88S		137

179	Sildenafil for pulmonary hypertension. 2004 , CD003562		12
178	Treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2004 , 351, 1425-36	59.2	1338
177	Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. 2004 , 3, 339-52		39
176	[Primary pulmonary hypertension: prospects for treatment]. 2004 , 122, 62-3		1
175	[Treatments for pulmonary arterial hypertension]. 2004 , 25, 720-31		2
174	Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. 2004 , 68, 75-103		242
173	Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. 2004 , 110, 3149-55		143
172	Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. 2004 , 125, 580-6		100
171	Pulmonary thromboembolism superimposed on a congenital ventricular septal defect in a 50-year-old man inhaled nitric oxide and sildenafil to the rescue. 2004 , 12, 188-90		14
170	Current Management of Pulmonary Hypertension. 2004 , 11, 40-53		4
169	Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension. 2004 , 43, 891-3		2
168	Idiopathic pulmonary arterial hypertension in children. 2005 , 17, 372-80		30
167	Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. 2005 , 69, 461-5		45
166	[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. 2005 , 64, 123-36		2
165	[Recommendations of the German Society of Rheumatology on therapy of pulmonary hypertension in patients with autoimmune diseases]. 2005 , 64, 93-5		
164	The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. 2005 , 17, 134-41		46
163	Hipertensi3 arterial pulmonar en el a3 2004. 2005 , 5, 90A-103A		
162	[Therapy of pulmonary arterial hypertension]. 2005 , 46, 341-9		0

161	Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. 2005 , 3, 26	26
160	Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. 2005 , 280, 12944-55	272
159	Oral sildenafil for treatment of severe pulmonary hypertension in an infant. 2005 , 88, 109-12	24
158	Pulmonary hypertension. 2005 , 172, 1072-7	37
157	Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. 2005 , 171, 275-81	193
156	Advances in the medical treatment of pulmonary hypertension. 2005 , 28, 311-24	4
155	[Treatment of pulmonary arterial hypertension]. 2005 , 34, 1445-55	2
154	Hipertensi3 arterial pulmonar. 2005 , 9, 1-7	
153	Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. 2005 , 99, 91-5	57
152	Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. 2005 , 100, 267-73	129
151	Oral sildenafil reduces pulmonary hypertension after cardiac surgery. 2005 , 79, 194-7; discussion 194-7	108
150	[Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. 2005 , 58, 523-66	21
149	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. 2005 , 6, 76	25
148	Drug treatment of pulmonary arterial hypertension: current and future agents. 2005 , 65, 1337-54	40
147	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. 2005 , 4, 531-40	18
146	Gu3as de Pr3ctica Cl3nica sobre el diagn3stico y tratamiento de la hipertensi3 arterial pulmonar. 2005 , 58, 523-566	
145	Hypertension art3rielle pulmonaire. 2005 , 2, 161-170	
144	Pulmonary vascular manifestations of mixed connective tissue disease. 2005 , 31, 451-64, vi	42

143	Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. 2006 , 4, 293-300	41
142	A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. 2006 , 151, 851.e1-5	169
141	Systemic and localized scleroderma. 2006 , 24, 374-92	98
140	Pulmonary hypertension in children. 2006 , 16, 237-247	11
139	Dramatic decrease in the pulmonary artery systolic pressure and disappearance of the interatrial shunt with sildenafil treatment in a patient with primary pulmonary hypertension with atrial septal aneurysm and a severe right to left shunt through the patent foramen ovale. 2006 , 110, 97-9	6
138	Hypertension artérielle pulmonaire. 2006 , 1, 1-7	
137	Hypertension artérielle pulmonaire. 2006 , 3, 1-27	2
136	Noninfectious Pulmonary Complications of HIV. 2006 , 13, 194-202	2
135	Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. 2006 , 25, 214-26	19
134	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. 2006 , 100, 2031-40	104
133	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366
132	Oral sildenafil citrate lacks genotoxicity and cytotoxicity in a primate model: <i>Callithrix jacchus</i> . 2006 , 26, 423-7	7
131	Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. 2006 , 29, 123-8	25
130	New insights in the treatment strategy for pulmonary arterial hypertension. 2006 , 20, 377-86	23
129	Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. 2006 , 26, 270-3	13
128	Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years. 2006 , 26, 68-94	12
127	Sildenafil citrate and fetal outcome in pregnant rats. 2006 , 21, 259-63	27
126	Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. 2006 , 16, 84-6	13

125	Treatment for Pulmonary Arterial Hypertension. 2006 , 99-118	1
124	Pulmonary Veno-occlusive Disease. 2006 , 157-169	
123	Pulmonary arterial hypertension: current therapeutic strategies. 2007 , 4, 319-29	46
122	Vasorelaxant effects of icariin on isolated canine coronary artery. 2007 , 49, 207-13	29
121	Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. 2007 , 83, 68-71; discussion 71	73
120	Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. 2007 , 120, 306-13	52
119	Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. 2007 , 21, 203-7	34
118	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. 2007 , 28, 143-67, ix	66
117	[Clinical efficacy of sildenafil in patients with pulmonary hypertension in functional class II or III]. 2007 , 43, 272-6	2
116	Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?. 2007 , 11, 110-2	9
115	Hipertensi3 pulmonar: eficacia cl3nica del sildenafilo en clases funcionales II-III. 2007 , 43, 272-276	8
114	PDE5 inhibitors and pulmonary hypertension. 2008 , 5, 171-178	
113	Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. 2008 , 80, 249-52	33
112	Out of the blue. 2009 , 2, 67-71	
111	Advances in therapies for pediatric pulmonary arterial hypertension. 2009 , 3, 265-82	4
110	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. 2009 , 122, 216-38	273
109	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. 2009 , 27, 13-23	18
108	Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. 2009 , 14, 284-90	15

107	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. 2009 , 3, 201-211		1
106	Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension. 2010 , 25, 313-8		7
105	Oral sildenafil: potential role in heart transplantation. Review of the literature and personal experience. 2010 , 55, 291-5		11
104	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. 2010 , 6, 273-80		21
103	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. 2010 , 4, 61-70		28
102	The use of sildenafil in persistent pulmonary hypertension of the newborn. 2010 , 27, 225-30		57
101	Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. 2010 , 14, R169		221
100	Current and future therapy for pulmonary hypertension in patients with right and left heart failure. 2010 , 8, 241-50		2
99	Emerging drugs for pulmonary hypertension. 2010 , 15, 71-85		11
98	Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. <i>Handbook of Experimental Pharmacology</i> , 2011 , 415-46	3.2	26
97	Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. 2011 , 54, 5607-11		96
96	Tadalafil for the treatment of pulmonary arterial hypertension. 2011 , 5, 315-28		7
95	P. 302-353		
94	A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. 2012 , 125, 324-34		265
93	[Pulmonary hypertension: from molecular pathophysiology to haemodynamic abnormalities]. 2012 , 29, 956-70		4
92	Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study. 2012 , 52, 425-31		6
91	Childhood Pulmonary Arterial Hypertension. 2012 , 1003-1018		
90	ULTIMATE-SHF trial (Udenafil Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. 2013 , 14, 188		7

89	Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats. 2013 , 3, 84-7	14
88	Enhancing cognition before clinical symptoms of dementia. 2014 , 8, 240	1
87	Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement. 2014 , 46, 281-5	10
86	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension. 2014 , 9, S79-91	4
85	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90	10
84	Effects of sildenafil on prognosis in patients with pulmonary hypertension after left-sided valvular surgery. 2014 , 23, 680-5	11
83	Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. 2014 , 128, 43-56	23
82	Phenylephrine activates eNOS Ser 1177 phosphorylation and nitric oxide signaling in renal hypertensive rat aorta. 2014 , 738, 192-9	13
81	Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. 2014 , 16, 89-107	25
80	Progress in the understanding and management of pulmonary arterial hypertension. 2015 , 2015, 13	3
79	Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension. 2015 , 2015, 762349	17
78	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. 2015 , 132, 2037-99	624
77	Selective Optimization of Side Activities (SOSA) in Drug Discovery. 2015 , 473-486	1
76	Current Treatment Strategies, Guidelines and New Therapies. 2015 , 81-145	
75	Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis. 2015 , 161, 333-8	9
74	Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. 2016 , 9, 251-9	17
73	Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. 2016 , 109, 431-43	73
72	Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension. 2016 , 254, 1167-74	7

71	Computational Tools To Model Halogen Bonds in Medicinal Chemistry. 2016 , 59, 1655-70	99
70	Targeting the NO-sGC-cGMP Pathway in Pulmonary Arterial Hypertension. 2017 , 139-151	1
69	Strategies for Tackling Drug Resistance in Tuberculosis. 2017 , 89-112	1
68	Looking Back, Looking Forward at Halogen Bonding in Drug Discovery. 2017 , 22,	86
67	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. 2018 , 137, e578-e622	264
66	Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies. 2018 , 38, 914-950	23
65	Bone Morphogenetic Protein-Based Therapeutic Approaches. 2018 , 10,	31
64	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. 2018 , 43, 191-216	1
63	Cardiac Physiology and Pharmacology. 2019 , 424-457.e17	1
62	Sildenafil for Pulmonary Arterial Hypertension. 2019 , 26, e520-e526	19
61	Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease. 2020 , 190, 111311	4
60	Non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease. 2020 , 10, 10012	7
59	Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis. 2020 , 11, 451	11
58	Off-label use of pulmonary vasodilators after left ventricular assist device implantation: Calling in the evidence. 2020 , 214, 107619	4
57	Transcriptional profiling indicates cAMP-driven reversal of HIV latency in monocytes occurs via transcription factor SP-1. 2020 , 542, 40-53	2
56	Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. 2021 , 44, 223-231	65
55	Sexual dysfunction in men and women with diabetes: a mirror of their complications?. 2021 ,	8
54	Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates. 2021 , 28, 2418-2437	2

53	Possible Beneficial Actions of Caffeine in SARS-CoV-2. 2021 , 22,		2
52	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. 2021 , 2, 63-78		
51	The NO - K ⁺ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. 2003 , 543, 293-322		16
50	Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. 2004 , 207-237		1
49	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161		1
48	Modulating cGMP to treat lung diseases. <i>Handbook of Experimental Pharmacology</i> , 2009 , 469-83	3.2	8
47	Anesthesia for Pediatric Cardiac Surgery. 2010 , 2599-2652		2
46	Sildenafil in HIV-related pulmonary hypertension. <i>Aids</i> , 2001 , 15, 1747-8	3.5	51
45	Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. <i>Aids</i> , 2002 , 16, 1568-9	3.5	39
44	Therapy of pulmonary hypertension: targeting pathogenic mechanisms with selective treatment delivery. <i>Critical Care Medicine</i> , 2001 , 29, 1086-7	1.4	5
43	Regulation and Function of Cyclic Nucleotide Phosphodiesterases in Vascular Smooth Muscle and Vascular Diseases. 2006 ,		1
42	Sildenafil reduces insulin-resistance in human endothelial cells. <i>PLoS ONE</i> , 2011 , 6, e14542	3.7	37
41	Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis. <i>Cardiology Research</i> , 2019 , 10, 369-377	1.8	6
40	[Collagen diseases with pulmonary hypertension]. <i>Japanese Journal of Clinical Immunology</i> , 2004 , 27, 127-36		1
39	Vasorelaxant Effect of Sildenafil on Aorta and Pulmonary Artery in Rabbits. <i>International Journal of Pharmacology</i> , 2005 , 2, 55-59	0.7	1
38	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		
37	This page intentionally left blank. 2005 , 48-48		
36	Childhood Pulmonary Arterial Hypertension. 2006 , 910-926		

- 35 Pulmonary Hypertension in Children. **2006**, 274-287
- 34 Molecular Aspects of Drug Actions: From Receptors to Effectors. **2006**, 1659-1677
- 33 Pulmonary Veno-occlusive Disease. **2006**, 832-841
- 32 Erectile Dysfunction and the Heart. **2006**, 367-373
- 31 Reinventing the Wheel. **2006**,
- 30 Combination therapy using inhaled iloprost and sildenafil in a patient with idiopathic pulmonary arterial hypertension. *Cor Et Vasa*, **2007**, 49, 222-224 0.3
- 29 Drug therapy: Sildenafil for post-operative pulmonary hypertension and Eisenmenger syndrome - A brief review of literature and survey of expert opinion. *Annals of Pediatric Cardiology*, **2008**, 1, 70-4 0.8
- 28 Nitric Oxide. **2009**, 1-6
- 27 Idiopathic and Familial Pulmonary Arterial Hypertension. **2010**, 39-84
- 26 Cor Pulmonale. **2010**, 1326-1355
- 25 Pathobiology and Treatment of Pulmonary Hypertension in HIV Disease. **2011**, 1033-1041
- 24 Pulmonary Veno-occlusive Disease. **2011**, 1169-1181
- 23 Idiopathic pulmonary arterial hypertension in children. **2011**, 559-571
- 22 Legochnaya arterial'naya gipertenziya: na puti ot ratsional'noy diagnostiki k vyboru effektivnoy lekarstvennoy terapii. *Systemic Hypertension*, **2013**, 10, 57-69 1.6 1
- 21 Strategies to Assess and Minimize Right Heart Failure After Left Ventricular Assist Device Implantation. **2014**, 113-129 2
- 20 Selective Pulmonary Vasodilators. **2015**, 809-836
- 19 Pathogenesis of Pulmonary Arterial Hypertension. *Respiratory Medicine*, **2015**, 37-65 0.2
- 18 The first Russian experience of sildenafil application in patients with idiopathic pulmonary hypertension. *Systemic Hypertension*, **2015**, 12, 50-55 1.6

17	A non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease.		
16	Reversible Acute Kidney Injury Associated with Sildenafil Overdose. <i>Cureus</i> , 2018 , 10, e3322	1.2	
15	Chronic Pulmonary Hypertension. 2020 , 465-489		
14	Ipertensione polmonare. 2007 , 197-203		
13	Phosphodiesterase-5 inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2013 , 218, 229-55	3.2	2
12	Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. <i>Texas Heart Institute Journal</i> , 2005 , 32, 405-10	0.8	18
11	Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. <i>Texas Heart Institute Journal</i> , 2011 , 38, 238-42	0.8	30
10	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. <i>Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery</i> , 2010 , 26, 206-218	0	1
9	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial. <i>European Journal of Heart Failure</i> ,	12.3	1
8	Pregnancy in Pulmonary Arterial Hypertension: A Multidisciplinary Approach. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 196	4.2	1
7	AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM. 2014 , 95-108		
6	APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION. 2015 , 42-49		2
5	Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients. 13,		0
4	Efficacy of tadalafil on improvement of men with erectile dysfunction caused by COVID-19: A randomized placebo-controlled trial. 2022 ,		
3	A Review on Computer-aided Chemogenomics and Drug Repositioning for Rational COVID -19 Drug Discovery.		1
2	Randomized Clinical and Biochemical Study Comparing the Effect of L-arginine and Sildenafil in Beta Thalassemia Major Children With High Tricuspid Regurgitant Jet Velocity. 2022 , 27, 107424842211326		0
1	How to Treat Right Heart Failure. Tips for Clinicians in Everyday Practice. 2023 , 19, 125-135		0